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Abstract Many osteoporotics have comorbid diabetes
mellitus (DM), hypertension (HT), and dyslipidemia (DL).
However, whether such comorbidities alter response to
anti-osteoporotic treatment is unknown. We did post hoc
analyses of combined data from three risedronate Japanese
phase III trials to determine whether the presence of DM,
HT, or DL affects its efficacy and safety. Data from 885
subjects who received 48-week treatment with risedronate
were collected and combined from the three phase III trials.
They were divided into two groups by the presence or
absence of comorbidities: DM (n = 53) versus non-DM
(n = 832); HT (n = 278) versus non-HT (n = 607); and
DL (n = 292) versus non-DL (n = 593). Bone mineral
density (BMD), urinary type 1 collagen N-telopeptide
(uNTX), and serum bone-specific alkaline phosphatase
(BAP) were measured at baseline and sequentially until
48 weeks. BMD or bone markers were not different
between any of the two groups. Overall, BMD was
increased by 5.52 %, and uNTX and BAP were decreased
by 35.4 and 33.8 %, respectively. Some bone markers were
slightly lower in DM and DL subjects, but the responses to
risedronate were not significantly different. Statin users had
lower uNTX and BAP, but showed no difference in the
treatment response. All the other medications had no
apparent effect. Adverse event incidence was marginally
higher in DL compared with non-DL (Relative risk 1.06;
95 % confidence interval 1.01–1.11), but was not related to
increase in any specific events. Risedronate shows consis-
tent safety and efficacy in suppressing bone turnover and
increasing BMD in osteoporosis patients with comorbid
DM, HT, and/or DL.
Keywords Bisphosphonate  Risedronate  Metabolic
syndrome  Life style-related disease  Bone mineral
density  Bone turnover markers
Introduction
Osteoporosis has become an epidemic in many aging
societies including Japan. So have the components of
metabolic syndrome including diabetes mellitus (DM),
hypertension (HT) and dyslipidemia (DL). These metabolic
diseases are not only very common, but closely related to
the life style, in part mechanistically interrelated [1, 2], and
may potentially affect bone metabolism. At the initiation of
anti-osteoporotic treatment many patients may have such
comorbidities and have been exposed to various medica-
tions for those comorbid conditions.
Epidemiological and clinical studies have established
that both type 1 and type 2 DM are associated with an
increased risk of fracture in part independently of bone
mineral density (BMD) [3–6]. Conflicting results have
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been reported as to the fracture risk and BMD in subjects
with HT, DL, and metabolic syndrome [7–14]. Moreover,
various medications for DM, HT, or DL have been
demonstrated to affect bone [15–20]. For example, it has
been shown that antidiabetic thiazolidinediones increase
fracture risk, whereas cholesterol-lowering statins, which
inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase in the mevalonate pathway, and anti-hy-
pertensive beta-blockers, which antagonize beta-adrenergic
receptors, may protect bone from fractures. However, little
is known whether comorbid DM, HT, DL or medications
for them have any influence on the efficacy and safety of
established anti-osteoporotic treatment.
In the present study, we analyzed whether comorbid DM,
HT, DL, and their medications altered bone response to
risedronate, a commonly prescribed oral bisphosphonate,
using the data of phase III clinical trials conducted in Japan.
Adverse effects were also analyzed to determine whether the
comorbidities and medications affected their occurrence.
Methods
Data Included in the Analyses
The present analysis was conducted using the combined
data from three randomized, double-blind phase III trials
for risedronate [21–23], which were carried out at multiple
medical institutions in Japan between March 1999 and July
2004. In the studies CCT-003 (48 weeks) and CCT-005
(96 weeks), the eligible patients were randomly assigned to
receive either a daily oral dose of 2.5 mg of risedronate or
an intermittent cyclical dosage regimen of etidronate con-
sisting of cycles of 2 weeks of treatment with 200 mg/day
followed by 10-week medication-free periods. In the study
CCT-101 (48 weeks), the eligible patients were randomly
assigned to receive either a 17.5 mg once-weekly dose or a
2.5 mg once-daily dose of risedronate. In all studies,
blinding to the study drug was maintained by a double-
dummy technique using active drugs and corresponding
placebo tablets.
All patients were supplemented with 1.54 g calcium
lactate (equivalent to 200 mg elemental calcium)
throughout the study period. The daily dose of calcium was
based on the result of the National Nutrition Survey con-
ducted by the Ministry of Health, Labor and Welfare
(recommended daily allowance of calcium for Japanese,
600 mg; actual intake, 585 mg on average in 1995) and the
necessary amount in the elderly estimated in a calcium
balance study (700–800 mg). Vitamin D was not supple-
mented in the three studies. Throughout the study period,
concomitant use of any drugs known to affect bone meta-
bolism was prohibited.
The study protocols were approved by the Institutional
Review Board of each institution prior to initiation of the
study, and all patients gave written informed consent
before registration.
Subjects
This post hoc analysis includes combined data from 885
osteoporosis patients who received treatment with rise-
dronate for 48 weeks in the three risedronate phase III
clinical trials in Japan, as described above. Ambulatory
patients of either sex, aged 40–75 years in the CCT-003
trial, 50 years or older in the CCT-005 and CCT-101 trials,
with involutional osteoporosis were eligible if they met the
diagnostic criteria for primary osteoporosis established by
the Committee of the Japanese Society for Bone and
Mineral Research (JSBMR) [24, 25]. Eligible women were
postmenopausal in CCT-003 and CCT-005 trials, and were
at least 2 years after the last menstruation in CCT-001.
Exclusion criteria included any secondary osteoporosis or
other diseases known to cause reduced bone mass, any
radiographic findings that might affect the vertebral
integrity, recent use of drugs known to affect bone meta-
bolism, serious renal, hepatic, or cardiac diseases, gas-
trointestinal diseases, drug hypersensitivity, malignant
tumors under treatment with antitumor agents, history of
radiotherapy to the lumbar spine or pelvis, and history of
treatment with risedronate. The presence or absence of
comorbid DM, HT, and DL were recorded based on
attending physicians’ diagnosis at the initiation of each
study. As for diabetes, subjects on insulin therapy were
excluded. Thus, although precise diagnosis of type 1 or 2
DM was not made, we assume that virtually no subjects
with type 1 DM should have been included.
Endpoints
In studies CCT-003 and CCT-101, the primary efficacy
endpoint was the percent change in mean L2–L4 BMD
from baseline to the time of final evaluation. In CCT-005,
the primary efficacy endpoint was the cumulative incidence
rate of new non-traumatic vertebral fracture (including
worsening of prevalent fracture) at the end of the treatment
period, expressed as the percentage of patients with at least
one new or worsening vertebral fracture. In the present
study, the effect of risedronate on BMD, bone resorption
markers [urinary N-terminal telopeptide of type 1 collagen
(NTX) and C-terminal telopeptide of type 1 collagen
(CTX)], and a bone formation marker [serum bone-specific
alkaline phosphatase (BAP)] was evaluated using the
combined data of the above studies.
The L2–L4 BMD was determined at baseline and after
12, 24, 36, and 48 weeks of treatment or at the time of
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withdrawal from the study by dual-energy X-ray absorp-
tiometry (DXA) with the use of QDR type, XR type, or
DPX type instruments in studies CCT-003 and CCT-101.
Biochemical markers of bone turnover were assessed at
baseline and after 4, 12, 24, 36, and 48 weeks of treatment
in studies CCT-003 and CCT-101, and at baseline and 24,
48, 72, and 96 weeks in study CCT-005.
Safety was assessed by the incidence of adverse events.
The objective symptoms and subjective signs related to
adverse effects were monitored by noting complaints at
each visit.
Statistical Analyses
Two-sample Student’s t tests were conducted for compar-
ison of age, body mass index (BMI), and baseline values
and percent changes from baseline of BMD and bone
markers, between groups with and without DM, HT, or DL.
One-sample Student’s t tests were conducted for compar-
ison of percent changes of BMD and absolute changes of
NTX from baseline. One-way ANOVA was used for
comparison of baseline values between groups according to
the number of complications. Confidence intervals of dif-
ference between groups with and without DM, HT, or DL
were determined. And confidence intervals of difference in
BMD and biochemical markers of groups with one, two,
and three complications were determined with the group
without complications as a reference. As for longitudinal
changes in BMD, interactions between time and the pres-
ence or absence of the three comorbidities were also
examined by linear mixed-effect modeling. Of 885 subjects
randomized and assigned to risedronate in the three studies,
baseline BMD data were unavailable in CCT-005 study
(N = 273), and CTX and BAP data were lacking in CCT-
003 study (N = 118) and CCT-005 study (N = 273). Some
data for BMD and biochemical markers of bone turnover at
48 weeks were missing because of early withdrawal or
protocol deviations. Results are presented as means ± SD.
Percent changes in BMD from the baseline were shown in
boxplots expressing median and interquartile range. All the
statistical analyses were done using SAS software, version
9.2 (SAS Institute Japan, Inc., Tokyo).
Results
Patient Characteristics at Baseline
Among the 885 subjects enrolled, those having DM, HT,
and DL were 53 (6.0 %), 278 (31.4 %), and 292 (33.0 %)
in number, respectively. Subjects with DM, HT, or DL
were significantly older than those without (Table 1). Of
the 53 patients with DM, two were taking TZD, and thirty
were taking other medications for DM. The majority of
patients with HT were taking calcium channel blockers
(69 %), and approximately equal numbers (18 %) were
taking angiotensin I converting enzyme inhibitors, angio-
tensin II receptor blockers, or other antihypertensives. Only
11 % were taking beta-blockers. Among 292 subjects with
DL, 170 (58 %) were taking statins. There were no dif-
ferences in BMD, BMI, urinary NTX or CTX, or serum
BAP levels at baseline between any of the groups, with a
few exceptions: Patients with DL had lower BAP, and
those with DM had lower NTX and CTX, compared with
those without. With respect to medications, subjects treated
with statins had lower BAP (28.6 ± 9.9 vs. 31.2 ± 10.2,
p = 0.02) and CTX (230.8 ± 104.5 vs. 265.9 ± 133.6,
p = 0.01) compared with non-statin users. No other med-
ications affected any bone parameters (data not shown).
While almost half of the study population (46.2 %,
409/885) had no components of metabolic syndrome,
38.8 % (343/885) had one, 13.4 % (119/885) had two, and
1.6 % (14/885) had all the three (Table 2). There were no
differences in BMD among groups according to the number
of comorbidities. Although the number of comorbidities
tended to be associated positively with age and BMI, and
negatively with bone turnover markers, the trend was not
statistically significant.
Bone Mineral Density
Following 48 weeks of treatment with risedronate, a sig-
nificant increase in BMD of the lumbar spine and decreases
in biochemical markers of bone turnover were observed.
Overall, risedronate treatment for 48 weeks resulted in
5.52 % increase in lumbar spine BMD. There was no dif-
ference in BMD gains between subjects with DM, HT, or
DL and those without each comorbidity (Fig. 1a). The
number of comorbidities did not influence BMD response
to risedronate treatment, either (Fig. 1b). A stratified
analysis by use versus non-use of treatment agents for
respective metabolic disorders showed no significant dif-
ference in BMD responses to treatment with risedronate.
Statin users, who had lower values of bone markers at
baseline, also showed similar BMD changes as compared
with statin non-users (data not shown). As for longitudinal
changes in BMD at 12, 24, 36, and 48 weeks, linear mixed-
effect modeling analysis also revealed no significant
interaction between time and the presence or absence of
each comorbidity (data not shown), indicating that none of
the three comorbid conditions affected time-dependent
effect of risedronate on BMD.
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Bone Turnover Markers
The presence or absence of each metabolic comorbidity did
not affect changes in bone turnover markers in response to
risedronate treatment (Table 3). The number of comor-
bidities also had no influence on the suppressive effect of
risedronate on bone turnover markers (Table 4). In par-
ticular, although subjects with DM tended to have lower
bone turnover at the baseline, treatment responses expres-
sed as percent changes were quite similar throughout the
treatment period both in terms of BMD (Fig. 2a) and bone
markers (Fig. 2b). And again, no medications influenced
the responses of bone turnover markers to risedronate
treatment (data not shown).
Adverse Event
The overall adverse event incidence was higher in the DL
group compared with the non-DL group with a marginal
significance (Table 5), but no specific adverse events were
related to this increase in the DL group. Incidence rate of
serious adverse effects was not increased in this group,
either. And neither DM nor HT caused a statistically sig-
nificant increase in the incidence rate of adverse events.
Vertebral Fracture
We observed a total of 33 new or worsened morphomet-
rical vertebral fractures during 48 weeks. Of the thirty-
three, fifteen were observed in patients without any
comorbidities, six in patients with HT ? DL, seven in
patients with HT, five in patients with DL, and no patients
with DM. The number of the vertebral fractures was too
small to determine the influence of comorbid metabolic
disorders.
Discussion
In the present study, we demonstrated consistent efficacy of
risedronate on BMD and bone turnover markers in osteo-
porosis patients irrespective of comorbid DM, HT, or DL.
Table 1 Baseline characteristics according to the presence or absence of comorbid diabetes, hypertension, or dyslipidemia
Diabetes Hypertension Dyslipidemia
Yes No Yes No Yes No
N 53 832 278 607 292 593
Age (years) 71.6 ± 6.6* 68.5 ± 8.1 72.1 ± 7.8* 67.1 ± 7.6 69.2 ± 8.0* 68.4 ± 8.0
Women (men) 46 (7) 807 (25) 267 (11) 586 (21) 288 (4) 565 (28)
BMI (kg/m2) 23.1 ± 3.2 22.1 ± 3.1 23.1 ± 3.3 21.8 ± 2.8 22.4 ± 3.0 22.1 ± 3.1
Lumbar spine BMD (g/cm2) 0.668 ± 0.094 0.669 ± 0.086 0.672 ± 0.090 0.668 ± 0.084 0.668 ± 0.079 0.670 ± 0.090
NTX (nmol BCE/mmolCr) 42.7 ± 20.3* 49.7 ± 22.8 48.9 ± 22.6 49.4 ± 22.7 48.6 ± 22.0 49.6 ± 23.0
CTX (lg/mmolCr) 197.1 ± 86.7* 262.5 ± 130.1 256.7 ± 115.5 259.4 ± 134.6 252.5 ± 131.2 262.2 ± 127.3
BAP (U/L) 28.2 ± 8.9 30.8 ± 10.3 31.3 ± 10.5 30.3 ± 10.0 29.5 ± 9.8* 31.4 ± 10.4
BMI Body mass index, BMD bone mineral density, NTX N-terminal telopeptide of type 1 collagen, CTX C-terminal telopeptide of type 1
collagen, BAP bone-specific alkaline phosphatase
* Significantly different from the group without each comorbidity (p\ 0.05)
Table 2 Baseline
characteristics according to the
number of comorbidities
Number of comorbidities
0 1 2 3
N 409 343 119 14
Age 67.1 ± 7.8 69.0 ± 7.9 72.7 ± 7.5 73.1 ± 7.4
Women (men) 394 (15) 331 (12) 114 (5) 14 (0)
BMI (kg/m2) 21.7 ± 2.8 22.3 ± 3.2 23.4 ± 3.2 22.9 ± 2.3
Lumbar spine BMD (g/cm2) 0.671 ± 0.089 0.663 ± 0.082 0.684 ± 0.082 0.646 ± 0.112
NTX (nmolBCE/mmolCr) 49.6 ± 22.5 50.0 ± 24.1 46.3 ± 17.7 45.3 ± 27.7
CTX (lg/mmolCr) 262.1 ± 128.6 264.0 ± 138.2 240.1 ± 98.9 193.9 ± 77.5
BAP (U/L) 31.0 ± 10.0 30.7 ± 10.7 30.1 ± 9.3 25.9 ± 8.3
BMI Body mass index, BMD bone mineral density, NTX N-terminal telopeptide of type 1 collagen, CTX
C-terminal telopeptide of type 1 collagen, BAP bone-specific alkaline phosphatase
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Commonly prescribed medications for those comorbidities
had little effects on risedronate responsiveness. Adverse
effects were also comparable among those with or without
those metabolic abnormalities.
Osteoporosis, and the three diseases analyzed here, are
very common among older people. Although what per-
centage of osteoporotics generally have DM, HT, or DL is
unknown, more than half of the participants of the current
study had at least one of the three comorbidities, suggest-
ing that their coincidence is frequent. Thus, it appears
clinically important to determine whether or not those
comorbidities affect the effect of standard treatment
modalities for osteoporosis.
Risedronate Effect on Subjects with Metabolic
Syndrome Components
The three life style-related metabolic diseases are not only
prevalent all over the world, but also partly shares a
common mechanism. The combination of the three is well
known as metabolic syndrome, fundamentally linked to
obesity and insulin resistance [1, 2, 26]. Association
between metabolic syndrome and osteoporosis has been
controversial [8–10]. Because insulin is considered to be
bone-anabolic [27–30], it seems plausible that insulin
resistance in bone [31] leads to loss of bone mass and/or
qualitative integrity. However, as has been the case with
type 2 DM, one reason for the difficulty in identifying
potentially detrimental effects of metabolic syndrome on
osteoporosis is the fact that BMD is generally positively
associated with BMI: because obesity is bone-protective, it
may mask the potential risk of osteoporosis associated with
insulin resistance per se as well as specific pathophysio-
logical changes caused by each component. In this sense, it
seems intriguing that, in our study, subjects with metabolic
syndrome components tended to have lower bone turnover,
as observed with NTX in DM. Even though the clinical
association of metabolic syndrome with osteoporosis and
its impact on bone metabolism has not been established,
our results suggest that risedronate can be safely and
effectively used for the treatment of osteoporosis compli-
cated with metabolic syndrome. As far as we know, this is
the first report demonstrating that a bisphosphonate is as
effective in subjects with metabolic syndrome components
as in those without.
Effect of Bisphosphonates on Diabetic Subjects
Of particular interest and importance is the effect of rise-
dronate on subjects with DM. Clinical association between
DM and fragility fracture has been established, although
the mechanism is not completely understood. Subjects with
type 2 DM has normal to high BMD despite increased risk
of fracture, suggesting that impaired bone quality con-
tributes to bone fragility [3–6, 29]. And some studies
describe that type 2 DM is associated with decreased bone
formation or low bone turnover, although conflicting
results are reported [32, 33]. One may assume that these
changes observed in type 2 DM could potentially blunt
responses to anti-resorptive therapy, which is expected to
increase BMD mainly by decreasing remodeling fre-
quency. Contrary to such an assumption, our results clearly
indicate that risedronate is equally effective in subjects
with type 2 DM at least in terms of BMD gain and turnover
suppression.
To date, no large-scale randomized controlled studies of
any anti-osteoporotic drug efficacy on diabetic patients has
been reported. The only study thus far published is the post
hoc analysis of the fracture intervention trial (FIT) study, in
which they examined whether the presence of diabetes
affect responsiveness to alendronate, another widely used
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Fig. 1 Percent changes in lumbar spine bone mineral density after
48 weeks of treatment with risedronate. The box denotes interquartile
range (IQR) with the band of median inside. Outliers more than 1.5
IQR above 75th percentile or below 25th percentile are shown in open
circles. Neither the presence or absence of each comorbid condition
(a) nor the number of comorbidities (b) affected gains in bone mineral
density by risedronate. DM diabetes, HT hypertension, DL
dyslipidemia
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compared to the non-diabetics, diabetics lost more bone at
the hip without treatment, but that the responses to alen-
dronate in terms of BMD and bone turnover markers were
similar between the two groups. These findings, as well as
our current observations, strongly support an idea that the
presence of diabetes has little effects on responsiveness to
bisphosphonates. Collectively, these results suggest that
bisphosphonates including risedronate are among the first
choices for osteoporosis treatment in diabetic patients as in
general population.
One important unsolved question is whether or not the
same efficacy of risedronate on BMD in diabetic patients
Table 3 Percent decreases in bone turnover markers after 48 weeks of treatment with risedronate according to the presence or absence of each
component of metabolic syndrome
Diabetes Hypertension Dyslipidemia
Yes No Yes No Yes No
NTX
N 44 682 214 512 242 484
Decrease rate (%) 25.5 ± 44.0 36.0 ± 37.6 35.7 ± 44.5 35.3 ± 35.0 36.5 ± 33.7 34.8 ± 40.1
Difference -10.5 0.4 1.7
95 % confidence interval -22.1–1.1 -5.6–6.5 -4.2–7.6
CTX
N 27 406 131 302 166 267
Decrease rate (%) 57.3 ± 28.9 55.1 ± 33.9 57.0 ± 25.0 54.5 ± 36.7 55.0 ± 39.5 55.4 ± 29.4
Difference 2.2 2.5 -0.4
95 % confidence interval -10.9–15.3 -4.4–9.4 -6.9–6.1
BAP
N 27 405 131 301 166 266
Decrease rate (%) 33.7 ± 16.7 33.8 ± 20.9 31.6 ± 20.2 34.7 ± 20.8 32.7 ± 21.5 34.4 ± 20.1
Difference -0.0 -3.1 -1.8
95 % confidence interval -8.1–8.0 -7.3–1.2 -5.8–2.3
NTX N-terminal telopeptide of type 1 collagen, CTX C-terminal telopeptide of type 1 collagen, BAP bone-specific alkaline phosphatase
Table 4 Percent decreases in
bone turnover markers after
48 weeks of treatment with
risedronate according to the
number of comorbidities
Number of complications
0 1 2 3
NTX
N 341 280 95 10
Decrease rate (%) 35.8 ± 34.4 34.7 ± 43.2 36.1 ± 34.8 34.4 ± 35.9
Difference 0 -1.1 0.3 -1.4
95 % confidence interval – -7.3–5.0 -7.6–8.1 -23.1–20.3
CTX
N 182 185 59 7
Decrease rate (%) 55.8 ± 29.4 53.4 ± 40.4 58.6 ± 21.2 64.8 ± 13.3
Difference 0 -2.4 2.8 9.0
95 % confidence interval – -9.7–4.9 -5.3–11.0 -13.0–31.1
BAP
N 181 185 59 7
Decrease rate (%) 35.4 ± 19.5 33.0 ± 22.6 31.9 ± 17.0 29.4 ± 21.8
Difference 0 -2.4 -3.5 -6.0
95 % confidence interval – -6.8–2.0 -9.1–2.1 -20.8–8.9
NTX N-terminal telopeptide of type 1 collagen, CTX C-terminal telopeptide of type 1 collagen, BAP bone-
specific alkaline phosphatase
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can translate into the same effect of fracture prevention.
This is particularly important considering the fact that
factors other than BMD, i.e., bone quality, largely con-
tributes to the fracture risk in subjects with type 2 DM. In
this sense, it is quite intriguing that fracture risk of subjects
with type 2 DM has been shown to be indeed higher than
that of non-diabetics at a given BMD but to be dependent
on BMD: the higher BMD is, the lower the fracture risk
becomes [35]. These results strongly suggest that, despite
the underlying BMD-independent mechanism of osteo-
porosis, increasing BMD can still be an effective mea-
sure to decrease the fracture risk in subjects with type 2
DM. Definitive conclusion should await future prospec-
tive studies of fracture prevention focusing on diabetic
subjects.
Drug Interaction with Risedronate
One of the interesting findings in the present study was the
fact that statin users had lower bone turnover markers at the
baseline, consistent with previous reports that statins
inhibit bone resorption while stimulating bone formation
[36]. Although statins and bisphosphonates potentially
share a common pathway in their inhibitory effect on bone
resorption, our results indicate that statins do not blunt
responsiveness to risedronate.
And no other drugs compromised risedronate effect in
the present study. These results argue against a possibility
that particular drugs affecting bone turnover may also
hamper risedronate effect.
Limitations
There are limitations in this study. First, this was a post hoc
analysis of pooled data from 3 trials, which were originally
neither intended to determine influence of comorbidities
nor randomized for their presence. Various potential con-
founders may have affected the presented results. Second,
the presence or absence of metabolic syndrome was not
determined according to its strict criteria, as the diagnosis
of metabolic syndrome components in the current study
were not based on actual values of biochemical tests. Third,
the number of subjects in some subgroups was small. We
were therefore unable to draw definitive conclusion espe-
cially about the influence of each medication as well as the
effect of risedronate in subjects with all the three comor-
bidities. Fourth, the current analysis did not assess rise-

























































Fig. 2 Time courses of changes in lumbar spine bone mineral density
and urinary NTX excretion by risedronate treatment in subjects with
or without diabetes. Error bars represent standard deviations.
*p\ 0.001, significantly different from baseline, **p\ 0.05, signif-
icantly different between the two groups. a Bone mineral density;
b urinary NTX
Table 5 Adverse event




Yes No Yes No Yes No
N 53 832 278 607 292 593
Adverse event incidence (%) 84.9 87.3 88.9 86.3 90.4 85.5
Relative risk 0.97 1.03 1.06
95 % confidence interval 0.87–1.09 0.98–1.08 1.01–1.11
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investigate anti-fracture efficacy of risedronate due to the
small sample number and the original study protocols not
designed for this purpose.
Conclusion
In summary, we demonstrated that the presence of DM,
HT, or DL had virtually no effects on bone response to
risedronate in subjects with osteoporosis. Commonly used
medications for those comorbidities did not have apparent
influence on risedronate effects, either. The profile of
adverse events was also similar regardless of the presence
of those metabolic diseases. We therefore conclude that
physicians can prescribe risedronate to patients with those
comorbidities with considerable confidence, expecting
consistent efficacy and safety.
Acknowledgments This study was supported by the Joint Devel-
opment Program of Ajinomoto Pharmaceuticals Co., Ltd. and Takeda
Pharmaceutical Co., Ltd. Funding for writing/editorial support was
provided by Ajinomoto Pharmaceuticals Co., Ltd.
Compliance with Ethical Standards
Conflict of Interest Dr. Daisuke Inoue reports personal fees from
Ajinomoto Pharmaceuticals, Grants from Astellas Pharma, Grants
from Asahi-Kasei Pharma, Grants from Chugai Pharmaceutical,
Grants from Daiichi-Sankyo, Grants from Eli Lilly Japan, Grants
from Eisai, Grants from Pfizer, Grants from Ono Pharmaceutical,
Grants from Taisho-Toyama Pharmaceutical, Grants from Takeda
Pharmaceutical, Grants from Teijin Pharma, outside the submitted
work. Mr. Ryoichi Muraoka reports personal fees from Ajinomoto
Pharmaceuticals Co. Ltd., during the conduct of the study. Dr. Ryo
Okazaki reports Grants from Ajinomoto Pharmaceuticals, Grants
from Astellas Pharma, Grants from Asahi-Kasei Pharma, Grants
from Chugai Pharmaceutical, Grants from Daiichi-Sankyo, Grants
from Eli Lilly Japan, Grants from Eisai, Grants from Pfizer, Grants
from Ono Pharmaceutical, Grants from Taisho-Toyama Phara-
maceutical, Grants from Takeda Pharmaceutical, Grants from Teijin
Pharma, outside the submitted work. Toshitsugu Sugimoto has
received research Grants from Eli Lilly Japan, Eisai, MSD, Taisho-
Toyama Pharmaceutical Co, Chugai Pharmaceutical, Daiichi-Sankyo
Co, Takeda Pharmaceutical, and Pfizer as well as consulting fee
from Asahi-Kasei Pharma Co. Yoshiki Nishizawa have none to
disclose.
Human and Animal Rights and Informed Consent All proce-
dures followed were in accordance with the ethical standards of the
institutional committee on human experimentation and with the
Helsinki Declaration of 1975, as revised in 2008. Informed consent
was obtained from all patients.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Gallagher EJ, Leroith D, Karnieli E (2011) The metabolic syn-
drome: from insulin resistance to obesity and diabetes. Med Clin
N Am 95(5):855–873. doi:10.1016/j.mcna.2011.06.001
2. O’Neill S, O’Driscoll L (2015) Metabolic syndrome: a closer
look at the growing epidemic and its associated pathologies. Obes
Rev 16(1):1–12. doi:10.1111/obr.12229
3. Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) Sys-
tematic review of type 1 and type 2 diabetes mellitus and risk of
fracture. Am J Epidemiol 166(5):495–505
4. Melton LJ, Leibson CL, Achenbach SJ, Therneau TM, Khosla S
(2008) Fracture risk in type 2 diabetes: update of a population-
based study. J Bone Miner Res 23(8):1334–1342
5. Vestergaard P (2007) Discrepancies in bone mineral density and
fracture risk in patients with type 1 and type 2 diabetes: a meta-
analysis. Osteoporos Int 18(4):427–444
6. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T
(2007) Bone mineral density is not sensitive enough to assess the
risk of vertebral fractures in type 2 diabetic women. Calcif Tissue
Int 80(6):353–358
7. Cui LH, Shin MH, Chung EK, Lee YH, Kweon SS, Park KS,
Choi JS (2005) Association between bone mineral densities and
serum lipid profiles of pre- and post-menopausal rural women in
South Korea. Osteoporos Int 16(12):1975–1981
8. Ahmed LA, Schirmer H, Berntsen GK, Fonnebo V, Joakimsen
RM (2006) Features of the metabolic syndrome and the risk of
non-vertebral fractures: the Tromso study. Osteoporos Int 17(3):
426–432
9. Dennison EM, Syddall HE, Aihie Sayer A, Martin HJ, Cooper C
(2007) Lipid profile, obesity and bone mineral density: the hert-
fordshire cohort study. QJM 100(5):297–303
10. von Muhlen D, Safii S, Jassal SK, Svartberg J, Barrett-Connor E
(2007) Associations between the metabolic syndrome and bone
health in older men and women: the Rancho Bernardo study.
Osteoporos Int 18(10):1337–1344
11. Vestergaard P, Rejnmark L, Mosekilde L (2009) Hypertension is
a risk factor for fractures. Calcif Tissue Int 84(2):103–111
12. Yamaguchi T, Kanazawa I, Yamamoto M, Kurioka S, Yamauchi
M, Yano S, Sugimoto T (2009) Associations between compo-
nents of the metabolic syndrome versus bone mineral density and
vertebral fractures in patients with type 2 diabetes. Bone 45(2):
174–179
13. Ilic K, Obradovic N, Vujasinovic-Stupar N (2013) The relation-
ship among hypertension, antihypertensive medications, and
osteoporosis: a narrative review. Calcif Tissue Int 92(3):217–227.
doi:10.1007/s00223-012-9671-9
14. Lee SH, Baek S, Ahn SH, Kim SH, Jo MW, Bae SJ, Kim HK,
Choe J, Park GM, Kim YH, Koh JM, Kim BJ, Kim GS (2014)
Association between metabolic syndrome and incident fractures
in Korean men: a 3-year follow-up observational study using
national health insurance claims data. J Clin Endocrinol Metab
99(5):1615–1622. doi:10.1210/jc.2013-3608
15. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud
KE, van der Klift M, Pols HA (2004) Use of statins and fracture:
results of 4 prospective studies and cumulative meta-analysis of
observational studies and controlled trials. Arch InternMed 164(2):
146–152
16. Reid IR, Gamble GD, Grey AB, Black DM, Ensrud KE, Browner
WS, Bauer DC (2005) Beta-blocker use, BMD, and fractures in
the study of osteoporotic fractures. J Bone Miner Res 20(4):
613–618
17. Nguyen ND, Wang CY, Eisman JA, Nguyen TV (2007) On the
association between statin and fracture: a Bayesian consideration.
Bone 40(4):813–820
D. Inoue et al.: Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes... 121
123
18. Monami M, Cresci B, Colombini A, Pala L, Balzi D, Gori F,
Chiasserini V, Marchionni N, Rotella CM, Mannucci E (2008)
Bone fractures and hypoglycemic treatment in type 2 diabetic
patients: a case-control study. Diabetes Care 31(2):199–203
19. Loke YK, Singh S, Furberg CD (2009) Long-term use of thia-
zolidinediones and fractures in type 2 diabetes: a meta-analysis.
CMAJ 180(1):32–39. doi:10.1503/cmaj.080486
20. Kanazawa I, Yamaguchi T, Yamamoto M, Sugimoto T (2010)
Relationship between treatments with insulin and oral hypo-
glycemic agents versus the presence of vertebral fractures in type
2 diabetes mellitus. J Bone Miner Metab 28(5):554–560
21. Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y,
Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi
Y, Orimo H (2002) A comparison of the effect of risedronate and
etidronate on lumbar bone mineral density in Japanese patients
with osteoporosis: a randomized controlled trial. Osteoporos Int
13(12):971–979
22. Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A,
Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y (2006)
Efficacy and tolerability of once-weekly administration of 17.5
mg risedronate in Japanese patients with involutional osteo-
porosis: a comparison with 2.5-mg once-daily dosage regimen.
J Bone Miner Metab 24(5):405–413
23. Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A,
Inoue T, Kaneda K, Morii H, Nawata H, Yamamoto K, Ohashi Y,
Orimo H (2004) A comparison of incidences of vertebral fracture
in Japanese patients with involutional osteoporosis treated with
risedronate and etidronate: a randomized, double-masked trial.
J Bone Miner Metab 22(5):469–478
24. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki
M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y,
Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diag-
nostic criteria for primary osteoporosis: year 2000 revision.
J Bone Miner Metab 19(6):331–337
25. Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokcbuchi T,
Gorai L, Nakamura T, Kushida K, Tanaka H, Ikai T, Ohhashi Y
(1998) Diagnostic criteria of primary osteoporosis. J Bone Miner
Metab 16:139–150
26. Bassi N, Karagodin I,Wang S, Vassallo P, Priyanath A,Massaro E,
Stone NJ (2014) Lifestyle modification for metabolic syndrome: a
systematic review. Am J Med 127(12):1242e1241–1210. doi:10.
1016/j.amjmed.2014.06.035
27. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti
A, Ducy P, Karsenty G (2010) Insulin signaling in osteoblasts
integrates bone remodeling and energy metabolism. Cell
142(2):296–308. doi:10.1016/j.cell.2010.06.003
28. Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D,
Faugere MC, Aja S, Hussain MA, Bruning JC, Clemens TL
(2010) Insulin receptor signaling in osteoblasts regulates post-
natal bone acquisition and body composition. Cell 142(2):309–
319. doi:10.1016/j.cell.2010.06.002
29. Hamann C, Kirschner S, Gunther KP, Hofbauer LC (2012) Bone,
sweet bone—osteoporotic fractures in diabetes mellitus. Nat Rev
Endocrinol 8(5):297–305. doi:10.1038/nrendo.2011.233
30. Klein GL (2014) Insulin and bone: recent developments. World J
Diabetes 5(1):14–16. doi:10.4239/wjd.v5.i1.14
31. Wei J, Ferron M, Clarke CJ, Hannun YA, Jiang H, Blaner WS,
Karsenty G (2014) Bone-specific insulin resistance disrupts
whole-body glucose homeostasis via decreased osteocalcin acti-
vation. J Clin Investig 124(4):1–13. doi:10.1172/jci72323
32. Shu A, Yin MT, Stein E, Cremers S, Dworakowski E, Ives R,
Rubin MR (2012) Bone structure and turnover in type 2 diabetes
mellitus. Osteoporos Int 23(2):635–641. doi:10.1007/s00198-
011-1595-0
33. Starup-Linde J, Eriksen SA, Lykkeboe S, Handberg A, Vester-
gaard P (2014) Biochemical markers of bone turnover in diabetes
patients: a meta-analysis, and a methodological study on the
effects of glucose on bone markers. Osteoporos Int 25(6):1697–
1708. doi:10.1007/s00198-014-2676-7
34. Keegan TH, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL
(2004) Effect of alendronate on bone mineral density and bio-
chemical markers of bone turnover in type 2 diabetic women: the
fracture intervention trial. Diabetes Care 27(7):1547–1553
35. Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer
ES, Ensrud KE, Donaldson MG, Cauley JA, Harris TB, Koster A,
Womack CR, Palermo L, Black DM, Study of Osteoporotic
Fractures Research G, Osteoporotic Fractures in Men Research
G, Health A, Body Composition Research G (2011) Association
of BMD and FRAX score with risk of fracture in older adults with
type 2 diabetes. JAMA 305(21):2184–2192. doi:10.1001/jama.
2011.715
36. Chuengsamarn S, Rattanamongkoulgul S, Suwanwalaikorn S,
Wattanasirichaigoon S, Kaufman L (2010) Effects of statins vs.
non-statin lipid-lowering therapy on bone formation and bone
mineral density biomarkers in patients with hyperlipidemia. Bone
46(4):1011–1015. doi:10.1016/j.bone.2009.12.023
122 D. Inoue et al.: Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes...
123
